Literature DB >> 19606494

Characterization of new arylsulfatase A gene mutations reinforces genotype-phenotype correlation in metachromatic leukodystrophy.

Martina Cesani1, Alessia Capotondo, Tiziana Plati, Lucia Sergi Sergi, Francesca Fumagalli, Maria Grazia Roncarolo, Luigi Naldini, Giancarlo Comi, Maria Sessa, Alessandra Biffi.   

Abstract

Metachromatic Leukodystrophy (MLD) is a rare inherited lysosomal storage disorder caused by the deficiency of Arylsulfatase A (ARSA). The disease manifests itself with a broad spectrum of clinical variants, all characterized by progressive neurodegeneration in the central and peripheral nervous systems. The correlation between mutations in the ARSA gene, residual enzymatic activity associated with the mutated alleles and patients' phenotype, which has been extensively drawn for common ARSA mutations, has recently been expanded to rare ones. In this context, functional studies on the rare allelic variances acquire particular relevance for patients' prognostic evaluation. Here we have characterized eight newly identified ARSA mutations, through lentiviral vector-based expression studies on cell lines and ARSA defective murine fibroblasts. In each case, the residual activity associated with the new mutant allele correlates well with the patient's phenotype. Therefore, our results confirm the importance of functional characterization of mutant alleles for a precise genotype-based classification and definition of prognosis in MLD patients, which is particularly relevant for pre-symptomatic diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19606494     DOI: 10.1002/humu.21093

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

Review 1.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

2.  Cerebral gray and white matter changes and clinical course in metachromatic leukodystrophy.

Authors:  Samuel Groeschel; Christine í Dali; Philipp Clas; Judith Böhringer; Morten Duno; Christian Krarup; Christiane Kehrer; Marko Wilke; Ingeborg Krägeloh-Mann
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

3.  A model of metformin mitochondrial metabolism in metachromatic leukodystrophy: first description of human Schwann cells transfected with CRISPR-Cas9.

Authors:  Nayibe Tatiana Sanchez-Álvarez; Paula Katherine Bautista-Niño; Juanita Trejos-Suárez; Norma Cecilia Serrano-Díaz
Journal:  Open Biol       Date:  2022-07-06       Impact factor: 7.124

Review 4.  Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective.

Authors:  Shanice Beerepoot; Stefan Nierkens; Jaap Jan Boelens; Caroline Lindemans; Marianna Bugiani; Nicole I Wolf
Journal:  Orphanet J Rare Dis       Date:  2019-11-04       Impact factor: 4.123

5.  Metallothioneins as dynamic markers for brain disease in lysosomal disorders.

Authors:  Martina Cesani; Eleonora Cavalca; Romina Macco; Giuseppe Leoncini; Maria Rosa Terreni; Laura Lorioli; Roberto Furlan; Giancarlo Comi; Claudio Doglioni; Daniele Zacchetti; Maria Sessa; Clemens R Scherzer; Alessandra Biffi
Journal:  Ann Neurol       Date:  2014-01       Impact factor: 10.422

6.  Identification of a novel mutation in ARSA gene in three patients of an Iranian family with metachromatic leukodystrophy disorder.

Authors:  Neda Golchin; Mohammadreza Hajjari; Reza Azizi Malamiri; Majid Aminzadeh; Javad Mohammadi-Asl
Journal:  Genet Mol Biol       Date:  2017-11-06       Impact factor: 1.771

7.  Identification of a missense ARSA mutation in metachromatic leukodystrophy and its potential pathogenic mechanism.

Authors:  Liyuan Guo; Bo Jin; Yidan Zhang; Jing Wang
Journal:  Mol Genet Genomic Med       Date:  2020-09-01       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.